Stroke Virtual Grand Rounds
An Elderly Woman With Atrial
Fibrillation and Cardioembolic
Stroke Risk
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: August 4, 2011
Expiration Date: August 4, 2013
Estimated Time of Completion: 45 minutes
Description
The purpose of this activity is to emphasize the association between atrial fibrillation and cardioembolic stroke and the essential role of indefinite anticoagulant therapy to manage the risk of stroke.
Learning Objectives
- Describe the mechanisms and characteristics of cardioembolic stroke in association with atrial fibrillation.
- Discuss risk stratification methods to determine the level of stroke risk in a patient with atrial fibrillation and guidelines to direct pharmacologic and nonpharmacologic strategies for managing this risk.
- Evaluate existing and emerging therapies for stroke prophylaxis in patients with atrial fibrillation.
Target Audience
This activity is directed to neurologists, primary care physicians, and other healthcare professionals who manage patients with cerebrovascular disease.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Edward Manno, MD
Head, Neurocritical Care Unit
Cleveland Clinic
Cleveland, Ohio
Faculty
David Garcia, MD
Associate Professor of Hematology/Oncology
University of New Mexico School of Medicine
Director, Anticoagulation Management Service
University of New Mexico Cancer Center
Albuquerque, New Mexico
Disclosures
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he may have a relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:
David Garcia, MD |
||
| Boehringer Ingelheim Pharmaceuticals |
Membership on advisory committee or review panel |
|
| Bristol-Myers Squibb Company | Membership on advisory committee or review panel |
|
| Daiichi Sankyo, Inc. | Membership on advisory committee or review panel |
|
| Ortho-McNeil Neurologics, Inc. | Membership on advisory committee or review panel |
|
The following faculty has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:
Edward Manno, MD
All other planners, CME staff, and content reviewers have no relevant financial relationships to disclose.
The Cleveland Clinic Foundation Center for Continuing Education acknowledges
an educational grant for support of this activity from:
Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership
This CME activity was produced by the
Cleveland Clinic Center for Continuing Education
and
